2394: hVIVO Secures £6m Influenza Human Challenge Trial Contract
From The Vox Markets Podcast by Vox Markets Podcast
May 7, 2026 · 6 min · Episode 2394
About this episode
Andrew Catchpole discusses hVIVO's £6 million influenza human challenge trial contract and its implications for antiviral treatments.
Watch on YouTube Andrew Catchpole, Chief Scientific Officer of hVIVO joins Martin Luke of Vox Markets to discuss hVIVO’s newly signed £6 million influenza human challenge trial contract. Andrew explains how the study will evaluate a prophylactic antiviral treatment using hVIVO’s specialist influenza challenge model, highlighting the speed and efficiency advantages of human challenge trials, the growing focus on antiviral therapies, and why hVIVO continues to attract global clients.
People in this episode
Host: Martin Luke
Guest: Andrew Catchpole
Topics covered
- influenza
- human challenge trials
- antiviral treatments
- clinical studies
- biotechnology
Keywords
- hVIVO
- influenza
- human challenge trial
- antiviral therapy
- clinical research
Mentioned in this episode
Organizations: hVIVO, Vox Markets
More episodes of The Vox Markets Podcast
- 2421: 2 P’s on a Pod: Small Cap Investing with Paul Hill & Paul Scott · June 12, 2026 · 1h 21m
- 2420: Poolbeg Pharma - POLB 001 Trial Activated as CRS Prevention Study Moves Into Patients · June 12, 2026 · 4 min
- 2419: Finseta Interview - Last week’s positive FY’25 results and ‘in line’ outlook · June 11, 2026 · 18 min
- 2418: ECR fine-tunes gold production process at Raglan · June 10, 2026 · 12 min
- 2417: Mindflair benefits as a key investment, CameraMatics secures €48m growth investment · June 10, 2026 · 10 min
- 2416: Will Great Western Mining's OTC listing boost liquidity? · June 8, 2026 · 8 min
Explore listener stats, chart rankings, contacts and more on the The Vox Markets Podcast podcast page.